Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD1.
The recommended and maximum dose of Anoro Ellipta (UMEC/VI 55/22 mcg) is one inhalation once a day. If a dose is missed the next dose should be taken at the usual time the next day1.
50% of patients with COPD still experience breathlessness on monotherapy3.
LAMA/LABAs demonstrate superior lung function and symptom improvements vs monotherapy4.
A pooled, post hoc subgroup analysis showed that in patients naive to COPD maintenance therapy, Anoro has demonstrated a 2.4x greater improvement in lung function vs tiotropium HandiHaler with a comparable safety profile5,6.
Start with Anoro. It could provide you and your patients a superior alternative to LAMA alone5,6.
Anoro is the only once-daily LAMA/LABA to demonstrate in-class superiority8.
In a head-to-head trial, Anoro Ellipta provided 1.4x superior lung function improvement vs Spiolto, another LAMA/LABA8.
Anoro also provided a 38% reduction in rescue medication usage vs Spiolto. The safety profiles were comparable between Spiolto and Anoro8.
Prescribe Anoro for superior lung function improvement compared with Spiolto8.
COPD assessment test (CAT) pad questionnaire to measure the impact of COPD on a person’s life.Order now
Ellipta inhalation training whistle that helps patients understand the correct inspiratory flow needed to use the Ellipta device.Order now
Ellipta Demonstration device for healthcare professionals to show patients how to use the Ellipta device correctly.Order now
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
Anoro and Ellipta are registered trademarks of the GlaxoSmithKline group of companies
I.H. Last updated: November 2019. PM-GB-UCV-WCNT-190010